Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTE-X19 in Relapsed/Refractory Mantle Cell Lymphoma
NCT02601313Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Nov 2015
- Primary completion
- Sep 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of brexucabtagene autoleucel in mantle cell lymphoma (MCL), sponsored by Kite Pharma. Primary endpoint: Objective Response Rate at 7.8 years. Started Nov 2015; status: completed.
02
Drugs
brexucabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02601313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601313.